A Phase 2 interventional study of RGH-896 and RGH-896 in Diabetic Peripheral Neuropathic Pain, sponsored by Forest Laboratories. Completed at 54 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-07-14.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Pain by AbbVie — none open to participants now, none under way, none of them phase 3. Pain · AbbVie.
Among the 19 studies in Pain by AbbVie, this one has the largest enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2009, is one of 14 in phase 2, and was the 5th registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →None of the 19 studies in Pain by AbbVie is open now. The open studies under Pain, anywhere →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 458 is above the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 155 across the 17 interventional studies, 86 across the 2 observational. Of the 19 that completed or were terminated, 16 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Pain by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: RGH-896
Drug: RGH-896
Drug: RGH-896
Drug: pregabalin
Drug: placebo
45 mg TID, capsules, 14 weeks.
30 mg TID, capsules, 14 weeks.
15 mg TID, capsules, 14 weeks.
100 mg, TID, capsules, 14 weeks.
Also known as: Lyrica
TID, capsules, 14 weeks.
Change in mean daily pain rating
Time frame: Baseline to Week 14
50% reduction in pain
Time frame: Baseline to Week 14
The record gives a start of Feb 2009 and a primary completion of Apr 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Radiprodil